Clinical Trials Logo

Pulmonary Fibrosis clinical trials

View clinical trials related to Pulmonary Fibrosis.

Filter by:

NCT ID: NCT05339724 Completed - Clinical trials for Platelet Levels and Mean Platelet Volume in Patients With CF

Platelets in Cystic Fibrosis Lung Inflammation

Start date: April 8, 2022
Phase:
Study type: Observational

Cystic fibrosis (CF) is a chronic multiorgan disorder caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Chronic airway infection by bacterial pathogens accounts for the progressive, suppurative pulmonary disease that leads to significant morbidity and mortality in patients with CF. Neutrophil recruitment to the lungs accounts the most important contributor to pulmonary destruction. However, there is evidence that platelets may also have an important role in the pathogenesis of inflammation. To our knowledge, there is few information in platelet levels in patients with cystic fibrosis during pulmonary exacerbation, chronic airway colonization and when stable.

NCT ID: NCT05337163 Completed - Lung Cancer Clinical Trials

A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

Start date: February 25, 2022
Phase:
Study type: Observational

The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method (includes chest CT examination or pathological examination).

NCT ID: NCT05227443 Completed - Lung Diseases Clinical Trials

Effects of Exercise Training on Respiratory Performance in Patients With Fibrosing Interstitial Lung Diseases

ET-fILD
Start date: January 16, 2020
Phase: N/A
Study type: Interventional

The current study recruited patients with fibrosing interstitial lung diseases (f-ILD) whatever was the underlying pathology. The investigators aimed to compare the effects of aerobic exercises for lower limbs (LL) versus upper limbs, lower limbs, and breathing exercises (ULB) on the peak exercise measurements that was measured using cardiopulmonary exercise testing (CPET), dyspnea and health related quality of life assessment in this group of patients.

NCT ID: NCT05173571 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Homecare Integral Support Program for IPF Patients

PSPi-IPF
Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Homecare patient support program especially designed for covering IPF patient needs, implemented for 12 months, for improving quality of life

NCT ID: NCT05154240 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

Start date: February 21, 2022
Phase: Phase 1
Study type: Interventional

The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018_055 in healthy subjects. The study will be conducted in 1 clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose [SAD]) and Part B (multiple ascending dose [MAD]).

NCT ID: NCT05146934 Completed - Clinical trials for Idiopathic Interstitial Pneumonia

The Relationship Between Hormone Sensitivity and Imaging of Idiopathic Interstitial Pneumonia by Artificial Intelligence

IIP
Start date: December 30, 2019
Phase:
Study type: Observational

Application of artificial intelligence deep learning algorithm to analyze the relationship between hormone sensitivity of idiopathic interstitial pneumonia and imaging features of high resolution CT.

NCT ID: NCT05134727 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Start date: November 18, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.

NCT ID: NCT05130970 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Start date: January 27, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).

NCT ID: NCT05113654 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Sleep Disorders in Idiopathic Pulmonary Fibrosis

Start date: April 26, 2016
Phase:
Study type: Observational

This diagnostic observational study was conducted to (1) investigate the prevalence of sleep-related breathing disorders and other sleep disorders in idiopathic pulmonary fibrosis in comparison to COPD, (2) identify characteristics of symptomatic and prognostic significance in idiopathic pulmonary fibrosis with/without sleep disorders, and (3) evaluate different tools for their ability to assess the risk of co-existing sleep disorders in idiopathic pulmonary fibrosis.

NCT ID: NCT05095363 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Palliative Care Planner (PCplanner)

Start date: March 16, 2022
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine the feasibility, acceptability, and evidence for clinical impact of a mobile app-based program called Palliative Care Planner (PCplanner) in addressing needs and promoting advance care planning discussions among patients with idiopathic pulmonary fibrosis and their clinicians.